The present disclosure relates generally to methods for treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of hematopoietic cells obtained from a candidate donor having a specific combination of KIR3DL1 and HLA-B alleles. Also disclosed herein are methods for protecting a leukemia patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT).

Radioprotection, Radiomitigation and Radiorecovery: Timed use of more widely available antiradiation agents in a kit for subjects affected by ionizing radiation, radiomimetic exposure and radio contamination. The method in the form of strategically timed preemptive and post-irradiation compositions; radioprotection, radiomitigation and radiorecovery formulations are comprised of various available anticorporation, antioxidant, decorporation, multi-mechanistic, pro-survival, pro-hematopoietic, anti-fibrotic and other novel ingredients in synergistic mixtures to be used in critically-timed manners. Radioprotection, radiomitigation and radiorecovery of a mammal prior to, during, just after or well-after exposure to ionizing radiation energy—alpha, beta, neutron, gamma, X-ray and damaging radiofrequency radiation—for long or short periods of time, and exposure to or contamination by radioactive elements or compounds such as radioiodine, radiostrontium, radiophosphorus, radiocobalt, radiocadmium, radiopollonium, radioradium, radiocesium, radiouranium, radioamericium, radiopollonium, radiocerium, radioindium, and the like. Radiomimetic protective method for mucosal exposure is also described.

Radioprotection, Radiomitigation and Radiorecovery: Timed use of more widely available antiradiation agents in a kit for subjects affected by ionizing radiation, radiomimetic exposure and radio contamination. The method in the form of strategically timed preemptive and post-irradiation compositions; radioprotection, radiomitigation and radiorecovery formulations are comprised of various available anticorporation, antioxidant, decorporation, multi-mechanistic, pro-survival, pro-hematopoietic, anti-fibrotic and other novel ingredients in synergistic mixtures to be used in critically-timed manners. Radioprotection, radiomitigation and radiorecovery of a mammal prior to, during, just after or well-after exposure to ionizing radiation energy—alpha, beta, neutron, gamma, X-ray and damaging radiofrequency radiation—for long or short periods of time, and exposure to or contamination by radioactive elements or compounds such as radioiodine, radiostrontium, radiophosphorus, radiocobalt, radiocadmium, radiopollonium, radioradium, radiocesium, radiouranium, radioamericium, radiopollonium, radiocerium, radioindium, and the like. Radiomimetic protective method for mucosal exposure is also described.

Disclosed herein is a pharmaceutical composition for use in the treatment or prevention of radiation-induced fibrosis, wherein the composition comprises an extract of Trigonella foenum-graecum and optionally pharmaceutically acceptable additives.

Disclosed herein is a pharmaceutical composition for use in the treatment or prevention of radiation-induced fibrosis, wherein the composition comprises an extract of Trigonella foenum-graecum and optionally pharmaceutically acceptable additives.

The invention relates to a formulation for use as a drug comprising at least colloidal silver, Sambucus Nigra extract, Primulae flos cum calycibus extract and/or Hypericum perforatum extract, and Pelargonium sidoides extract. Preferentially, said formulation is used for prophylaxis and/or for antiviral, antibacterial and antifungal treatment. Even more preferentially, said formulation is an antifungal and antibacterial cream.

The invention relates to a formulation for use as a drug comprising at least colloidal silver, Sambucus Nigra extract, Primulae flos cum calycibus extract and/or Hypericum perforatum extract, and Pelargonium sidoides extract. Preferentially, said formulation is used for prophylaxis and/or for antiviral, antibacterial and antifungal treatment. Even more preferentially, said formulation is an antifungal and antibacterial cream.

An object is to provide an external composition for skin capable of easily enhancing body balance ability even for ordinary people such as housewives, students, middle-aged and mature-aged males and females, and elderly persons who do not aggressively exercise on a routine basis other than athletes. The object has been solved by an external composition for skin including a rhodochrosite extract extracted from rhodochrosite with water, a hematite extract extracted from hematite with water, a smithsonite extract extracted from smithsonite with water, and an olivine extract extracted from olivine with water, and the like.

An object is to provide an external composition for skin capable of easily enhancing body balance ability even for ordinary people such as housewives, students, middle-aged and mature-aged males and females, and elderly persons who do not aggressively exercise on a routine basis other than athletes. The object has been solved by an external composition for skin including a rhodochrosite extract extracted from rhodochrosite with water, a hematite extract extracted from hematite with water, a smithsonite extract extracted from smithsonite with water, and an olivine extract extracted from olivine with water, and the like.

Clay delivery systems for providing antimicrobial compositions are provided. The delivery systems include a two-part active excipient system that delivers clay for various applications of use, including topical applications. The two-part delivery system can include a first part comprising suspending agent(s), poloxamer and optionally a gellant, and a second part that is simultaneously delivered therewith comprising one or more nonionic EO-PO block copolymers in a water-based system. The delivery systems beneficially provide clays in a stable system that also unexpectedly accelerate the release of the clay into the water system for activation and delivery that is enhanced by the poloxamers into the tissue or organ of the body in need of treatment thereof.